fromilid uno 500 mg tabletki o zmodyfikowanym uwalnianiu
inpharm sp. z o.o. - tabletki o zmodyfikowanym uwalnianiu - 500 mg
fromilid uno 500 mg tabletki o zmodyfikowanym uwalnianiu
forfarm sp. z o.o. - clarithromycinum - tabletki o zmodyfikowanym uwalnianiu - 500 mg
fromilid uno 500 mg tabletki o zmodyfikowanym uwalnianiu
pharmapoint sa - clarithromycinum - tabletki o zmodyfikowanym uwalnianiu - 500 mg
fromilid uno 500 mg tabletki o przedłużonym uwalnianiu
inpharm sp. z o.o. - clarithromycinum - tabletki o przedłużonym uwalnianiu - 500 mg
fromilid uno 500 mg tabletki o przedłużonym uwalnianiu
medezin sp. z o.o. - clarithromycinum - tabletki o przedłużonym uwalnianiu - 500 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
bicardiol 2,5 mg tabletki powlekane
accord healthcare polska sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 2,5 mg
bicardiol 5 mg tabletki powlekane
accord healthcare polska sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 5 mg
bicardiol 10 mg tabletki powlekane
accord healthcare polska sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 10 mg
morysa 10 mg tabletki powlekane
neuraxpharm bohemia s.r.o. - memantini hydrochloridum - tabletki powlekane - 10 mg